HER3-DXd results have been reported in clinical trials, including a phase 1/2 study in patients with HER3-expressing ABC (NCT02980341) [22], a phase 2 trial among patients with ABC (NCT04699630) [23], as well a window-of-opportunity trial in early-stage breast cancer [24]. This evidence concerns the gene ERBB3 and breast carcinoma.